Quantum Biopharma receives Lucid-MS study report

Mr. Zeeshan Saeed reports QUANTUM BIOPHARMA ANNOUNCES POSITIVE RESULTS OF THE CLINICAL STUDY REPORT (CSR) FOR THE PHASE 1 MULTIPLE ASCENDING DOSE (MAD) CLINICAL TRIAL OF EXPERIMENTAL MULTIPLE SCLEROSIS DRUG LUCID-21-302 (LUCID-MS) Through Quantum Biopharma Ltd.'s subsidiary, Huge Biopharma Australia Pty. Ltd., the company has received the clinical study report for the trial entitled "A Phase 1, Randomised, Double-Blind, Placebo-Controlled, Multiple Ascending Dose Study to Evaluate the Safety and Pharmacokinetics of Lucid-MS in Healthy Adult Participants." The CSR concludes that there were no safety or tolerability concerns that were identified in healthy participants following treatment with consecutive daily dosing of Lucid-MS. Lucid-MS is a first-in-class, non-immunomodulatory, neuroprotective compound with a unique mechanism of action for the treatment of multiple sclerosis. It is a patented new chemical entity that has been shown in preclinical models to prevent demyelination, which is a hallmark of MS and other neurogenerative diseases and is characterized by damage to the myelin sheath surrounding nerve fibres. "We are thrilled that we now have the CSR for the phase 1 MAD trial and that Lucid-MS was found to be safe and well tolerated in healthy participants. The CSR allows us to advance the clinical development of Lucid-MS as it is a critical component of the investigational new drug application with the FDA," said Dr. Andrzej Chruscinski, vice-president of clinical and scientific affairs at Quantum Biopharma. "Results and observations from the first-in-human studies including this MAD investigation give us the confidence that Lucid-MS is safe and tolerable in healthy volunteers," said Dr. Lakshmi P. Kotra, director at Quantum Biopharma and a professor at the University of Toronto, who led the discovery of Lucid-MS. "Quantum team is preparing for the launch of efficacy trials in patients with MS, which is very exciting. This compound follows a novel non-immunomodulatory mechanism, and we are very excited to be planning human efficacy trials." About Quantum Biopharma Ltd. Quantum Biopharma is a biopharmaceutical company dedicated to building a portfolio of innovative assets and biotech solutions for the treatment of challenging neurodegenerative and metabolic disorders and alcohol misuse disorders with drug candidates in different stages of development. Through its wholly owned subsidiary, Lucid Psycheceuticals Inc., Quantum Biopharma is focused on the research and development of its lead compound, Lucid-MS. Lucid-MS is a patented new chemical entity shown to prevent and reverse myelin degradation, the underlying mechanism of multiple sclerosis, in preclinical models. Quantum Biopharma invented unbuzzd and spun out its over-the-counter version to a company, Unbuzzd Wellness Inc. (formerly Celly Nutrition Corp.), led by industry veterans. Quantum Biopharma retains ownership of 20.11 per cent (as of March 31, 2025) of Unbuzzd Wellness. The agreement with Unbuzzd Wellness also includes royalty payments of 7 per cent of sales from unbuzzd until payments to Quantum Biopharma total $250-million. Once $250-million is reached, the royalty drops to 3 per cent in perpetuity. Quantum Biopharma retains 100 per cent of the rights to develop similar products or alternative formulations specifically for pharmaceutical and medical uses. Quantum Biopharma maintains a portfolio of strategic investments through its wholly owned subsidiary, FSD Strategic Investments Inc., which represents loans secured by residential or commercial property. We seek Safe Harbor.